Chinthalapally V Rao from the University of Oklahoma Health Sciences Center, Oklahoma City, OK, US, talks to us about the protective role of aspirin and other NSAIDs in colorectal cancer.
1. What is currently known about the protective role of aspirin and other NSAIDs in colorectal cancer? (0:08)
2. Could you tell us a little about your recent study investigating intermittent dosing regimens of naproxen and aspirin in colon adenoma? (0:30)
3. How often and for how long should naproxen and aspirin be taken to achieve a protective effect? (1:18)
4. What are the limitations of this approach? (1:41)
5. What future studies are planned? (2:15)
Speaker disclosures: Chinthalapally V Rao has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
NSAIDS = non-steroidal anti-inflammatory drugs
Share this Video
Related Videos In Gastrointestinal Oncology
Jared Weiss, ESMO 2021: The Efficacy and Safety Findings of the KRYSTAL-1 Study
touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation. Questions 1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? […]
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!